Efficacy and Safety of Lacosamide in Painful Diabetic Neuropathy by Ziegler, Dan et al.
Efﬁcacy and Safety of Lacosamide in
Painful Diabetic Neuropathy
DAN ZIEGLER, MD, FRCP(E)
1
TIBOR HIDV´ EGI, MD
2
IRINA GURIEVA, MD
3
SABINE BONGARDT, MS
4
RAINER FREYNHAGEN, MD
5
DAVID SEN, PHD
6
KENNETH SOMMERVILLE, MD
6
ON BEHALF OF THE LACOSAMIDE SP743
STUDY GROUP*
OBJECTIVE — To evaluate efﬁcacy and safety of lacosamide compared with placebo in
painful diabetic polyneuropathy.
RESEARCH DESIGN AND METHODS — Diabetic patients with at least moderate
neuropathicpainwererandomizedtoplaceboorlacosamide400(inasloworstandardtitration)
or 600 mg/day over 6-week titration and 12-week maintenance periods. Primary efﬁcacy crite-
rion was intra-individual change in average daily Numeric Pain Rating Scale score from baseline
to the last 4 weeks.
RESULTS — For the primary end point, pain reduction was numerically but not statistically
greaterwithlacosamidecomparedwithplacebo(400mg/day,P0.12;600mg/day,P0.18).
Bothdosesweresigniﬁcantlymoreeffectivecomparedwithplacebooverthetitration(P0.03,
P  0.006), maintenance (P  0.01, P  0.005), and entire treatment periods (P  0.03, P 
0.02). Safety proﬁles between titration schemes were similar.
CONCLUSIONS — Lacosamidereducedneuropathicpainandwaswelltoleratedindiabetic
patients, but the primary efﬁcacy criterion was not met, possibly due to an increased placebo
response over the last 4 weeks.
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U
p to one in four patients with
diabetes may be affected by chro-
nic diabetic painful neuropathy
(DPN) (1,2) and suffer substantial mor-
bidity and impaired quality of life (3).
Because the current treatment options
are limited, there is continued need for
new therapeutic approaches (3,4). La-
cosamide is an anticonvulsant with a
unique mode of action, selectively en-
hancing slow inactivation of voltage-
gated sodium channels (5–8). This trial
was one of three similarly designed pla-
cebo-controlled, parallel-group trials to
evaluate the efﬁcacy of lacosamide in
DPN (9,10) using 400 mg/day (two ti-
tration schemes) and 600 mg/day.
RESEARCH DESIGN AND
METHODS — This trial (SP743, Clini-
calTrials.gov identiﬁer NCT00238524),
conducted December 2003 to January
2005 at 52 European sites, was ap-
proved by Institutional Review Boards
and met with the International Confer-
ence on Harmonisation–Good Clinical
Practice (ICH-GCP) guidelines and lo-
cal laws. All patients signed written in-
formed consent before participation.
Study population
Eligibility criteria were as follows: pa-
tients aged 18 years with type 1 or type
2 diabetes, symptomatic DPN for 6
months to 5 years (score 4o na n1 1 -
pointNumericPainRatingScale[NPRS]),
and A1C 12%). Exclusion criteria are
described in supplemental Appendix A,
which is available online at http://care.
diabetesjournals.org/cgi/content/full/
dc09-1578/DC1. Concomitant acetamino-
phen 2 g/day was permitted as rescue
medication.
Trial design
This 18-week, double-blind, placebo-
controlled trial began with a 1-week
washout and a 1-week baseline period for
pain assessments. Eligible patients were
randomized (1:2:2) to placebo or oral la-
cosamide, 400 or 600 mg/day, and then
entered a 6-week titration period fol-
lowed by a 12-week maintenance period.
To ensure blinding, trial medication and
packaging were identical in appearance,
and all dosing was twice daily. The 400
mg/day group was further randomized to
receive slow titration (100 mg/day for 3
weeks, followed by weekly increases of
100 mg/day, to 400 mg/day target dose at
week 6) or a standard titration (100 mg/
day,withweeklyincreasesof100mg/day,
to 400 mg/day target dose for titration
weeks 4–6). The 600 mg/day group fol-
lowed standard titration increasing by
100 mg/day each week. No back titration
was allowed.
Outcomes
The primary outcome was intra-individual
change in average daily (24-h) pain score
(11-pointNPRS;0nopain,10worst
possible pain) from baseline to average
score over the last 4 weeks of the mainte-
nance period. Secondary measures in-
cluded within-subject change in average
dailypainscorefrombaselinetoeachtrial
period (titration, maintenance, and entire
treatment). Additional secondary mea-
sures are described in supplemental
Appendix A. Safety evaluations on all pa-
tients receiving one or more doses of trial
medication (safety set) included adverse
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relevant laboratory changes, 12-lead
electrocardiogram, vital signs, and
physical and neurological examina-
tions. Statistical methods are described
in supplemental Appendix A.
RESULTS— Of513patientsscreened,
357wererandomizedandreceivedoneor
more doses of trial medication, 355 com-
prised the ITT population, and 246 com-
pleted the trial (CONSORT diagram
shown in supplemental Appendix Figure
B1). All groups showed similar demo-
graphic and baseline characteristics, al-
though numerically, more patients in the
placebo group reported severe pain
(NPRS8)atbaseline(supplementalAp-
pendix Table B1). Medical history and
concomitant diseases were similar across
treatment groups and were as expected in
a DPN population. Concomitant medica-
tion use was similar across groups.
Reductions in average daily pain
scores from baseline to the last 4 weeks of
the maintenance period (primary end
point) were greater in both the lacos-
amide 400 and 600 mg/day groups com-
pared with placebo, although differences
were not statistically signiﬁcant, possibly
related to increased placebo effect toward
the end of the trial (P  0.12, P  0.18;
Fig. 1). However, both lacosamide doses
weresigniﬁcantlymoreeffectivethanpla-
ceboinreducingaveragedailypainscores
when assessed for the titration period
(P  0.03, P  0.01) and maintenance
period (P  0.01, P  0.01), and entire
treatment period (titration period 
maintenance period; P  0.03, P  0.02;
detailed description provided in supple-
mental Appendix Table C1).
Inadditiontotheconsistencyofeffect
on NPRS scores through the total treat-
ment period with lacosamide, persistent
and clinically relevant effects were ob-
served for the secondary efﬁcacy mea-
suressuchaspatients’perceptionsofpain
using the Visual Analog Scale (VAS), the
Patients’ Global Impression of Change
(PGIC), and pain interference with sleep
and activity (supplemental Appendix C).
Generally, pain reductions were only
slightly higher in the lacosamide 600
mg/day group than the lacosamide 400
mg/day group and may have been af-
fected by higher dropout rates and less
tolerability with the 600 mg/day dose.
Adverse events occurring in 5% of
lacosamide-treated patients included diz-
ziness, fatigue, nausea, vertigo, headache,
andvomiting;exceptforfatigue,thesead-
verse events appeared to be dose related
(supplemental Appendix Table D1).
Changes in laboratory variables, vital
signs, body weight, and ﬁndings from
physical and neurological examinations
revealednoissuesofclinicalconcern.Ad-
verseeventincidencewassimilarbetween
the 400 mg/day slow and standard titra-
tion groups during the titration period
(slow, 46% [35/77]; standard, 49% [36/
73]). Adverse events resulting in with-
drawal occurred at an incidence of 13.0%
versus 8.2% for the 400 mg/day standard
and slow titration groups, respectively.
CONCLUSIONS — In this trial, laco-
samide did not result in statistically sig-
niﬁcant pain reductions over placebo for
the primary outcome. However, lacos-
Figure1—Meanchangefrombaselineinaveragedailypainscoreateachtrialvisit(weeks2,4,5,6,10,14,and18)forobservedcases(OC:patients
stillinthetrialatthetimeoftheclinicvisitorduringthatvisitinterval)andlastobservationcarriedforward(LOCF).BL,baseline;LCM,lacosamide;
MP, maintenance period.
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was sustained and signiﬁcantly greater
than placebo through the titration, main-
tenance, and entire treatment periods. Per-
sistent and clinically relevant effects were
also observed for the secondary efﬁcacy
measures (PGIC, VAS, and pain interfer-
ence with sleep and activity). Titration
schemes did not affect tolerability.
The increased placebo response ob-
served at the end of the maintenance pe-
riod, with almost a quarter of the placebo
group experiencing a 50% reduction in
pain score in the last 4 weeks, may have
contributedtothelackofstatisticalsignif-
icanceintheprimaryendpoint.Highpla-
cebo responses are not unusual in
neuropathic pain studies (11–14). Be-
cause of the relatively long titration, this
trial is among the longest conducted in
patients with DPN. In trials of DPN, pla-
cebo response does not plateau, but in-
creases over time, such that longer trials
areatgreaterriskfordecreasedseparation
of drug effect from placebo (14).
In conclusion, lacosamide resulted in
numerically greater pain reductions over
placebo, but for the primary efﬁcacy vari-
able of change in average pain score from
baseline to the last 4 weeks of mainte-
nance period, the differences were not
statistically signiﬁcant, possibly related to
a marked increase in placebo response
during the last 4 weeks of the trial.
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